Zeus Hygia Lifesciences introduces BioSOLVE Technology for increased bioavailability

Logo courtesy of Zeus Hygia Lifesciences Pvt Ltd.

Zeus Hygia Lifesciences Pvt Ltd. (Hyderabad, India) launched BioSOLVE Technology, a patent-pending delivery system that offers higher bioavailability, efficacy, and potency for water-insoluble active ingredients by utilizing a food-grade encapsulating excipients. 

“The fact that more ingredients are being introduced into the marketplace for novel product development is attractive, yet a fair number of those exhibit poor solubility and bioavailability, and eventually the end user, being consumers, get minimal therapeutic benefits,” said Arunkanth Krishnakumar, Zeus Hygia co-founder and director of business development and strategies, in a press release. “Our goal was to innovate a platform technology that overcomes these inherent deficiencies to allow them to be used effectively in a wide range of consumer-friendly product delivery forms including but not limited to tablets and capsules.”

The generally recognized as safe (GRAS), hydrophilic carrier system has unique emulsifying properties and forms adequate hydrophilic/lipophilic balance around the bioactive molecules, leading to enhanced absorption by the gut wall. The improved bioavailability is due to several factors, including an increase in water solubility with better dissolution properties, as well as finer and uniform particles with larger surface area. The technology also enables manufacturers to use less of an ingredient for the same deliverable impact. 

“Consumers are quite sophisticated in their knowledge of how supplements work as well as why to take them, and they are equally passionate about obtaining benefits of supplementation in a variety of forms,” said Shankaranarayanan Jeyakodi, Zeus Hygia co-founder, and director of technical operations, in a press release. “Zeus BioSOLVE Technology offers manufacturers an opportunity to develop truly innovative health-promoting products. In other words, we have removed the formulation limitations.”